Myovant Sciences Ltd (NYSE:MYOV) insider Frank Karbe purchased 8,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were acquired at an average price of $9.10 per share, with a total value of $72,800.00. Following the completion of the acquisition, the insider now owns 8,000 shares of the company’s stock, valued at $72,800. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of MYOV traded down $0.31 on Tuesday, reaching $8.89. 196,402 shares of the stock traded hands, compared to its average volume of 185,157. The stock has a market cap of $705.38 million, a PE ratio of -2.17 and a beta of 1.31. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 21.51. Myovant Sciences Ltd has a 12 month low of $8.69 and a 12 month high of $27.45.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley grew its position in Myovant Sciences by 180.9% in the first quarter. Morgan Stanley now owns 3,590 shares of the company’s stock valued at $85,000 after acquiring an additional 2,312 shares during the period. BlackRock Inc. grew its position in Myovant Sciences by 5.2% in the fourth quarter. BlackRock Inc. now owns 27,912 shares of the company’s stock valued at $458,000 after acquiring an additional 1,386 shares during the period. Swiss National Bank grew its position in Myovant Sciences by 3.3% in the first quarter. Swiss National Bank now owns 31,200 shares of the company’s stock valued at $745,000 after acquiring an additional 1,000 shares during the period. Bank of New York Mellon Corp grew its position in Myovant Sciences by 3,012.4% in the fourth quarter. Bank of New York Mellon Corp now owns 369,320 shares of the company’s stock valued at $6,060,000 after acquiring an additional 357,454 shares during the period. Finally, Norges Bank bought a new stake in Myovant Sciences in the fourth quarter valued at $12,308,000. Institutional investors and hedge funds own 30.56% of the company’s stock.
A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Myovant Sciences from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a report on Wednesday, April 3rd. Evercore ISI assumed coverage on Myovant Sciences in a report on Thursday, April 11th. They set an “outperform” rating for the company. ValuEngine lowered Myovant Sciences from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. JMP Securities reiterated a “buy” rating and set a $25.00 price target on shares of Myovant Sciences in a report on Monday, February 11th. Finally, Barclays upgraded Myovant Sciences from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $22.00 to $25.00 in a report on Wednesday, February 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $26.83.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Recommended Story: Buy-Side Analysts
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.